How useful are cholinesterase inhibitors in the treatment of Alzheimer's Disease? A number needed to treat analysis

International Journal of Geriatric Psychiatry

Volumn 15, Issue 3, 2000, Pages 203-207

  Livingston, Gill ^a   Katona, Cornelius ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's Disease; Dementia; Numbers Needed to Treat; Systematic review

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; METRIFONATE; RIVASTIGMINE; TACRINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LIVER TOXICITY; QUANTITATIVE ASSAY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK MANAGEMENT; TREATMENT OUTCOME; UNITED KINGDOM;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 0034027804     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1166(200003)15:3<203::AID-GPS100>3.0.CO;2-9     Document Type: Article

References (10)

1. Altman, D. G. (1998) Confidence intervals for the number needed to treat. Br. Med. J. 317, 1309-1312.
2. Cookson, J. and Duffett, R. (1998) Fluoxetine: therapeutic and undesirable effects. Hospital Med. 59, 623-626.
3. Cook, R. J. and Sackett, D. L. (1995) The number needed to treat: a clinically useful measure of treatment effect. Br. Med. J. 310, 452-454.
4. Corey-Bloom, J., Anand, R. and Veach, J. (1998) A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate) a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's Disease. Int. J. Geriat. Psychopharm. 1, 55-65.
5. Guyatt, G. H., Sackett, D. L. and Cook, D. J. (1994) User's guide to the medical literature II. How to use an article about therapy or prevention. J. Am. Med. Assoc. 271, 59-63.
6. Knapp, M. J., Knopman, D. S., Solomon, P. R., Pendlebury, W. W., Davis, C. S. and Gracon, S. I. (1994) A 30 week randomised controlled trial of high dose tacrine in patients with Alzheimer's Disease. J. Am. Med. Assoc. 271, 985-991.
7. Moher, D., Fortin, P., Jadad, A. R., Juni, P., Klassen, T., Le Lorier, J., et al (1996) Completeness of reporting trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet 347, 363-366.
8. Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R. and Friedhoff, L. T. (1998) A 24-week, double-blind placebo-controlled trial of donepezil in patients with Alzheimer's Disease. Neurology 50, 136-145.
9. Rosler, M., Anand, R., Cicin-Sain, A., et al (1999) Efficacy and safety of rivastigmine in patients with Alzheimer's Disease. Results of an international, 26-week, multicentre, randomised, placebo-controlled trial. Br. Med. J. 318, 633-638.
10. Xu, S. S., Gao, Z. X., Wen, Z., et al (1995) Efficacy of tablet huperzine-A on memory cognition and behaviour in Alzheimer's Disease. Chung Kuo Yao Li H Sueh Pao 16, 391-395.